CN107278205A - 用作抗癌药的取代的核苷衍生物 - Google Patents
用作抗癌药的取代的核苷衍生物 Download PDFInfo
- Publication number
- CN107278205A CN107278205A CN201680011823.1A CN201680011823A CN107278205A CN 107278205 A CN107278205 A CN 107278205A CN 201680011823 A CN201680011823 A CN 201680011823A CN 107278205 A CN107278205 A CN 107278205A
- Authority
- CN
- China
- Prior art keywords
- alkyl
- hydrogen
- hydroxyl
- cancer
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CC(C)C[C@@]([C@@](*)[C@]([C@@](*)C[C@]([n]1c(N=CCC=C2N)c2nc1)O)O)N Chemical compound CC(C)C[C@@]([C@@](*)[C@]([C@@](*)C[C@]([n]1c(N=CCC=C2N)c2nc1)O)O)N 0.000 description 21
- QWIAHMVNMONKCU-UHFFFAOYSA-N Cc1ncnc2c1cc[nH]2 Chemical compound Cc1ncnc2c1cc[nH]2 QWIAHMVNMONKCU-UHFFFAOYSA-N 0.000 description 3
- CZMLCMOUGCMWFA-PLNGDYQASA-N C/C=C\c1c(C)ncnc1C Chemical compound C/C=C\c1c(C)ncnc1C CZMLCMOUGCMWFA-PLNGDYQASA-N 0.000 description 1
- YQRJSXJHZQLNCX-PHDIDXHHSA-N CC(C)([C@@H](CC1)O[C@H]1N)O Chemical compound CC(C)([C@@H](CC1)O[C@H]1N)O YQRJSXJHZQLNCX-PHDIDXHHSA-N 0.000 description 1
- BLFJUWOUOPYDHP-XQVHRTOBSA-N C[C@@H](C1OC(C)CC1)c(cc1)cc(F)c1F Chemical compound C[C@@H](C1OC(C)CC1)c(cc1)cc(F)c1F BLFJUWOUOPYDHP-XQVHRTOBSA-N 0.000 description 1
- ZWPYBFJDYDLLJD-WGLFHAEBSA-N C[C@@H](CC1)OC1[C@@H](c(cc1)cc(F)c1F)F Chemical compound C[C@@H](CC1)OC1[C@@H](c(cc1)cc(F)c1F)F ZWPYBFJDYDLLJD-WGLFHAEBSA-N 0.000 description 1
- ARTCXJGCMYSPSV-LWXNQMLSSA-N C[C@@H]([C@H]([C@H]([C@H]([n](cc1)c2c1c(C)ncn2)O)[O]#C)O)[C@@H](c1ccnc(N(C)C)c1)O Chemical compound C[C@@H]([C@H]([C@H]([C@H]([n](cc1)c2c1c(C)ncn2)O)[O]#C)O)[C@@H](c1ccnc(N(C)C)c1)O ARTCXJGCMYSPSV-LWXNQMLSSA-N 0.000 description 1
- ZQGBYLVSLUPNJY-DPZFQJAZSA-N C[C@@H]([C@H]([C@H]([C@H]([n]1c2nc(N)nc(C)c2cc1)O)O)O)[C@@H](c(cc1)cc(F)c1Cl)O Chemical compound C[C@@H]([C@H]([C@H]([C@H]([n]1c2nc(N)nc(C)c2cc1)O)O)O)[C@@H](c(cc1)cc(F)c1Cl)O ZQGBYLVSLUPNJY-DPZFQJAZSA-N 0.000 description 1
- BLPNMFYSTXNPRA-CELJHQOASA-N C[C@@H]([C@H]([C@H]([C@H]1O)[O]#C)O[C@H]1[n]1c(CN=CN=C(C2)N=C)c2nc1)O Chemical compound C[C@@H]([C@H]([C@H]([C@H]1O)[O]#C)O[C@H]1[n]1c(CN=CN=C(C2)N=C)c2nc1)O BLPNMFYSTXNPRA-CELJHQOASA-N 0.000 description 1
- PKKNCXMMSQGGEH-RWONEVQGSA-N C[C@H]([C@H]([C@H]([C@H]1O)O)O[C@H]1[n]1c(N=CN=[IH]=C2N)c2nc1)O Chemical compound C[C@H]([C@H]([C@H]([C@H]1O)O)O[C@H]1[n]1c(N=CN=[IH]=C2N)c2nc1)O PKKNCXMMSQGGEH-RWONEVQGSA-N 0.000 description 1
- CGWYOBCRCVTPCD-DLBZAZTESA-N Cc1c(cc[n]2[C@@H](CCC[C@@H](c(cc3)ccc3F)O)O)c2ncn1 Chemical compound Cc1c(cc[n]2[C@@H](CCC[C@@H](c(cc3)ccc3F)O)O)c2ncn1 CGWYOBCRCVTPCD-DLBZAZTESA-N 0.000 description 1
- CGWYOBCRCVTPCD-IAGOWNOFSA-N Cc1c(cc[n]2[C@@H](CCC[C@H](c(cc3)ccc3F)O)O)c2ncn1 Chemical compound Cc1c(cc[n]2[C@@H](CCC[C@H](c(cc3)ccc3F)O)O)c2ncn1 CGWYOBCRCVTPCD-IAGOWNOFSA-N 0.000 description 1
- UPZRLNSBZRVUAI-RUINGEJQSA-N Cc1ncnc2c1cc[n]2CC(CC1)O[C@@H]1C(c(cc1)cc(F)c1F)=O Chemical compound Cc1ncnc2c1cc[n]2CC(CC1)O[C@@H]1C(c(cc1)cc(F)c1F)=O UPZRLNSBZRVUAI-RUINGEJQSA-N 0.000 description 1
- BPTCCCTWWAUJRK-UHFFFAOYSA-N Clc1c(cc[nH]2)c2ncn1 Chemical compound Clc1c(cc[nH]2)c2ncn1 BPTCCCTWWAUJRK-UHFFFAOYSA-N 0.000 description 1
- KOJURFLWNZUGAX-JTRQHRHOSA-N N[C@@H](C(C[C@H]1O)O[C@H]1[n](cc1)c2c1cncn2)c(cc1)cc(F)c1F Chemical compound N[C@@H](C(C[C@H]1O)O[C@H]1[n](cc1)c2c1cncn2)c(cc1)cc(F)c1F KOJURFLWNZUGAX-JTRQHRHOSA-N 0.000 description 1
- PEHVGBZKEYRQSX-UHFFFAOYSA-N Nc1ncnc2c1cc[nH]2 Chemical compound Nc1ncnc2c1cc[nH]2 PEHVGBZKEYRQSX-UHFFFAOYSA-N 0.000 description 1
- WSJHYNQJBOXITQ-JTTNIQEDSA-N O[C@@H]([C@H]([C@H]([C@H]1O)O)O[C@H]1[n]1c2nc(Cl)ncc2c(F)c1)c(cc1F)ccc1F Chemical compound O[C@@H]([C@H]([C@H]([C@H]1O)O)O[C@H]1[n]1c2nc(Cl)ncc2c(F)c1)c(cc1F)ccc1F WSJHYNQJBOXITQ-JTTNIQEDSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/14—Pyrrolo-pyrimidine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/167—Purine radicals with ribosyl as the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/24—Heterocyclic radicals containing oxygen or sulfur as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562119932P | 2015-02-24 | 2015-02-24 | |
| US62/119,932 | 2015-02-24 | ||
| US201562213801P | 2015-09-03 | 2015-09-03 | |
| US62/213,801 | 2015-09-03 | ||
| US201662279209P | 2016-01-15 | 2016-01-15 | |
| US62/279,209 | 2016-01-15 | ||
| PCT/IB2016/050803 WO2016135582A1 (en) | 2015-02-24 | 2016-02-15 | Substituted nucleoside derivatives useful as anticancer agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107278205A true CN107278205A (zh) | 2017-10-20 |
Family
ID=55451515
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201680011823.1A Pending CN107278205A (zh) | 2015-02-24 | 2016-02-15 | 用作抗癌药的取代的核苷衍生物 |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US10428104B2 (enExample) |
| EP (1) | EP3262057B1 (enExample) |
| JP (1) | JP6584521B2 (enExample) |
| KR (1) | KR20170119705A (enExample) |
| CN (1) | CN107278205A (enExample) |
| AU (2) | AU2016225133B2 (enExample) |
| BR (1) | BR112017017396A2 (enExample) |
| CA (1) | CA2921314A1 (enExample) |
| CL (1) | CL2017002155A1 (enExample) |
| CO (1) | CO2017008403A2 (enExample) |
| CR (1) | CR20170384A (enExample) |
| CU (1) | CU20170105A7 (enExample) |
| DO (1) | DOP2017000195A (enExample) |
| EA (1) | EA031895B1 (enExample) |
| ES (1) | ES2792899T3 (enExample) |
| GT (1) | GT201700189A (enExample) |
| IL (1) | IL253637A0 (enExample) |
| MX (1) | MX2017010844A (enExample) |
| NI (1) | NI201700095A (enExample) |
| PE (1) | PE20171449A1 (enExample) |
| PH (1) | PH12017501413A1 (enExample) |
| SG (1) | SG11201706050WA (enExample) |
| SV (1) | SV2017005514A (enExample) |
| TN (1) | TN2017000357A1 (enExample) |
| TW (1) | TWI622595B (enExample) |
| UA (1) | UA118315C2 (enExample) |
| UY (1) | UY36564A (enExample) |
| WO (1) | WO2016135582A1 (enExample) |
| ZA (1) | ZA201705092B (enExample) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111542525A (zh) * | 2017-10-26 | 2020-08-14 | 普莱鲁德疗法有限公司 | 蛋白质精氨酸甲基转移酶5(prmt5)的选择性抑制剂 |
| CN112679505A (zh) * | 2020-12-25 | 2021-04-20 | 杭州澳赛诺生物科技有限公司 | 一种4-甲基-7H-吡咯并[2,3-d]嘧啶的合成方法 |
| CN114127072A (zh) * | 2019-03-25 | 2022-03-01 | 加利福尼亚技术学院 | Prmt5抑制剂及其用途 |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR104326A1 (es) | 2015-05-04 | 2017-07-12 | Lilly Co Eli | Compuestos nucleósidos 5-sustituidos |
| TWI730980B (zh) | 2015-08-26 | 2021-06-21 | 比利時商健生藥品公司 | 使用作為ｐｒｍｔ５抑制劑之新穎經６-６雙環芳香環取代之核苷類似物 |
| JP6909799B2 (ja) * | 2016-03-10 | 2021-07-28 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｐｒｍｔ５阻害剤として使用するための置換ヌクレオシドアナログ |
| AU2017230658B2 (en) | 2016-03-10 | 2021-03-04 | Janssen Pharmaceutica Nv | Substituted nucleoside analogues for use as PRMT5 inhibitors |
| SI3512857T1 (sl) | 2016-09-14 | 2021-07-30 | Janssen Pharmaceutica Nv | Spiro biciklični zaviralci interakcije menin-MLL |
| US12084462B2 (en) | 2016-09-14 | 2024-09-10 | Janssen Pharmaceutica Nv | Spiro bicyclic inhibitors of menin-MLL interaction |
| TWI753016B (zh) | 2016-09-14 | 2022-01-21 | 比利時商健生藥品公司 | Menin-mll相互作用之稠合二環抑制劑 |
| WO2018065365A1 (en) | 2016-10-03 | 2018-04-12 | Janssen Pharmaceutica Nv | Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors |
| AU2017338269B2 (en) | 2016-10-03 | 2021-03-25 | Janssen Pharmaceutica Nv | Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as PRMT5 inhibitors |
| US10745409B2 (en) | 2016-12-15 | 2020-08-18 | Janssen Pharmaceutica Nv | Azepane inhibitors of menin-MLL interaction |
| WO2018152548A1 (en) * | 2017-02-20 | 2018-08-23 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
| WO2018152501A1 (en) * | 2017-02-20 | 2018-08-23 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
| WO2018154104A1 (en) | 2017-02-27 | 2018-08-30 | Janssen Pharmaceutica Nv | Use of biomarkers in identifying cancer patients that will be responsive to treatment with a prmt5 inhibitor |
| WO2018160855A1 (en) | 2017-03-01 | 2018-09-07 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
| EP3939986A1 (en) * | 2017-08-09 | 2022-01-19 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
| BR112020010815A2 (pt) | 2017-12-08 | 2020-11-10 | Janssen Pharmaceutica Nv | análogos espirobicíclicos |
| CU24621B1 (es) | 2017-12-13 | 2022-09-08 | Lupin Ltd | Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5 |
| US11396517B1 (en) | 2017-12-20 | 2022-07-26 | Janssen Pharmaceutica Nv | Exo-aza spiro inhibitors of menin-MLL interaction |
| JP7328241B2 (ja) * | 2018-03-14 | 2023-08-16 | プレリュード セラピューティクス，インコーポレイティド | タンパク質アルギニンメチルトランスフェラーゼ５（ｐｒｍｔ５）の選択的阻害剤 |
| US10711007B2 (en) | 2018-03-14 | 2020-07-14 | Prelude Therapeutics Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) |
| GB201810092D0 (en) | 2018-06-20 | 2018-08-08 | Ctxt Pty Ltd | Compounds |
| EP3833669A4 (en) * | 2018-08-07 | 2022-05-11 | Merck Sharp & Dohme Corp. | PRMT5 INHIBITORS |
| KR20210129051A (ko) * | 2019-02-13 | 2021-10-27 | 프렐루드 테라퓨틱스, 인코포레이티드 | 단백질 아르기닌 메틸트랜스퍼라제 5(prmt5)의 선택적 억제제 |
| US12440506B2 (en) | 2019-04-05 | 2025-10-14 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) |
| TW202112375A (zh) | 2019-06-06 | 2021-04-01 | 比利時商健生藥品公司 | 使用ｐｒｍｔ５抑制劑治療癌症之方法 |
| PH12021553082A1 (en) | 2019-06-10 | 2023-09-11 | Lupin Ltd | Prmt5 inhibitors |
| KR20220019766A (ko) | 2019-06-12 | 2022-02-17 | 얀센 파마슈티카 엔.브이. | 신규 스피로바이사이클릭 중간체 |
| PL4299135T3 (pl) | 2019-06-18 | 2025-11-12 | Pfizer Inc. | Pochodne benzizoksazolosulfonamidu |
| EP4031555A1 (en) | 2019-09-18 | 2022-07-27 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
| JP7624985B2 (ja) | 2019-10-22 | 2025-01-31 | ルピン・リミテッド | Ｐｒｍｔ５阻害剤の組合せ医薬 |
| CN115135651A (zh) | 2019-12-03 | 2022-09-30 | 鲁皮恩有限公司 | 作为prmt5抑制剂的被取代的核苷类似物 |
| IL293965A (en) | 2019-12-19 | 2022-08-01 | Janssen Pharmaceutica Nv | History of Spiro straight chain transformed |
| CA3192099A1 (en) | 2020-08-18 | 2022-02-24 | Incyte Corporation | Process and intermediates for preparing a jak inhibitor |
| WO2022040172A1 (en) | 2020-08-18 | 2022-02-24 | Incyte Corporation | Process and intermediates for preparing a jak1 inhibitor |
| US20240101589A1 (en) * | 2020-10-08 | 2024-03-28 | Strom Therapeutics Limited | Inhibitors of mettl3 |
| WO2022153161A1 (en) | 2021-01-14 | 2022-07-21 | Pfizer Inc. | Treatment of cancer using a prmt5 inhibitor |
| JP2024526762A (ja) | 2021-07-12 | 2024-07-19 | インサイト・コーポレイション | Ｊａｋ阻害剤を調製するためのプロセス及び中間体 |
| US20250188110A1 (en) * | 2021-08-13 | 2025-06-12 | Albert-Ludwigs-Universität Freiburg | Specific small molecule inhibitors that block kmt9 methyltransferase activity and function |
| WO2024170488A1 (en) | 2023-02-13 | 2024-08-22 | Astrazeneca Ab | Prmt5 inhibitor for use in cancer therapy |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6492348B1 (en) * | 1998-06-23 | 2002-12-10 | Smithkline Beecham Corporation | Adenosine derivatives |
| US20040043960A1 (en) * | 2002-08-15 | 2004-03-04 | Jeff Zablocki | Partial and full agonists of A1 adenosine receptors |
| CN107580602A (zh) * | 2015-05-04 | 2018-01-12 | 伊莱利利公司 | 5’‑取代的核苷类似物 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5795977A (en) * | 1989-09-15 | 1998-08-18 | Metabasis Therapeutics, Inc. | Water soluble adenosine kinase inhibitors |
| US5646128A (en) * | 1989-09-15 | 1997-07-08 | Gensia, Inc. | Methods for treating adenosine kinase related conditions |
| US5864033A (en) * | 1989-09-15 | 1999-01-26 | Metabasis Therapeutics, Inc. | Adenosine kinase inhibitors |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| US6831069B2 (en) * | 1999-08-27 | 2004-12-14 | Ribapharm Inc. | Pyrrolo[2,3-d]pyrimidine nucleoside analogs |
| EP2623104A1 (en) * | 2009-03-20 | 2013-08-07 | Alios Biopharma, Inc. | Substituted nucleoside and nucleotide analogs |
| US20120077814A1 (en) | 2010-09-10 | 2012-03-29 | Zhong Wang | Sulfonamide, sulfamate, and sulfamothioate derivatives |
| WO2013009735A1 (en) * | 2011-07-13 | 2013-01-17 | Merck Sharp & Dohme Corp. | 5'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
| WO2013044030A1 (en) * | 2011-09-23 | 2013-03-28 | Enanta Pharmaceuticals, Inc. | 2'-chloroacetylenyl substituted nucleoside derivatives |
| EP3160477A4 (en) * | 2014-06-25 | 2018-07-04 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| WO2017024310A1 (en) * | 2015-08-06 | 2017-02-09 | Chimerix, Inc. | Pyrrolopyrimidine nucleosides and analogs thereof useful as antiviral agents |
-
2016
- 2016-02-15 CN CN201680011823.1A patent/CN107278205A/zh active Pending
- 2016-02-15 UA UAA201708102A patent/UA118315C2/uk unknown
- 2016-02-15 BR BR112017017396A patent/BR112017017396A2/pt not_active Application Discontinuation
- 2016-02-15 EP EP16707209.9A patent/EP3262057B1/en active Active
- 2016-02-15 MX MX2017010844A patent/MX2017010844A/es unknown
- 2016-02-15 EA EA201791563A patent/EA031895B1/ru not_active IP Right Cessation
- 2016-02-15 TN TNP/2017/000357A patent/TN2017000357A1/en unknown
- 2016-02-15 CU CUP2017000105A patent/CU20170105A7/xx unknown
- 2016-02-15 JP JP2017544584A patent/JP6584521B2/ja not_active Expired - Fee Related
- 2016-02-15 PE PE2017001447A patent/PE20171449A1/es unknown
- 2016-02-15 AU AU2016225133A patent/AU2016225133B2/en not_active Ceased
- 2016-02-15 WO PCT/IB2016/050803 patent/WO2016135582A1/en not_active Ceased
- 2016-02-15 ES ES16707209T patent/ES2792899T3/es active Active
- 2016-02-15 SG SG11201706050WA patent/SG11201706050WA/en unknown
- 2016-02-15 CR CR20170384A patent/CR20170384A/es unknown
- 2016-02-15 KR KR1020177026762A patent/KR20170119705A/ko not_active Ceased
- 2016-02-17 US US15/045,679 patent/US10428104B2/en active Active
- 2016-02-19 TW TW105104968A patent/TWI622595B/zh not_active IP Right Cessation
- 2016-02-19 CA CA2921314A patent/CA2921314A1/en not_active Abandoned
- 2016-02-22 UY UY0001036564A patent/UY36564A/es not_active Application Discontinuation
-
2017
- 2017-07-24 IL IL253637A patent/IL253637A0/en unknown
- 2017-07-26 ZA ZA2017/05092A patent/ZA201705092B/en unknown
- 2017-07-28 NI NI201700095A patent/NI201700095A/es unknown
- 2017-08-08 PH PH12017501413A patent/PH12017501413A1/en unknown
- 2017-08-14 SV SV2017005514A patent/SV2017005514A/es unknown
- 2017-08-17 CO CONC2017/0008403A patent/CO2017008403A2/es unknown
- 2017-08-21 DO DO2017000195A patent/DOP2017000195A/es unknown
- 2017-08-24 GT GT201700189A patent/GT201700189A/es unknown
- 2017-08-24 CL CL2017002155A patent/CL2017002155A1/es unknown
-
2018
- 2018-12-11 AU AU2018278842A patent/AU2018278842A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6492348B1 (en) * | 1998-06-23 | 2002-12-10 | Smithkline Beecham Corporation | Adenosine derivatives |
| US20040043960A1 (en) * | 2002-08-15 | 2004-03-04 | Jeff Zablocki | Partial and full agonists of A1 adenosine receptors |
| CN107580602A (zh) * | 2015-05-04 | 2018-01-12 | 伊莱利利公司 | 5’‑取代的核苷类似物 |
Non-Patent Citations (3)
| Title |
|---|
| CHRISTA E. MÜLLER ET AL.: "Recent developments in adenosine receptor ligands and their potential as novel drugs", 《BIOCHIMICA ET BIOPHYSICA ACTA》 * |
| DONGHANG CHENG ET AL.: "Small Molecule Regulators of Protein Arginine Methyltransferases", 《THEJOURNAL OFBIOLOGICAL CHEMISTRY》 * |
| KANCHAN DEVKOTA ET AL.: "Analogues of the Natural Product Sinefungin as Inhibitors of EHMT1 and EHMT2", 《ACS MEDICINAL CHEMISTRY LETTERS》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111542525A (zh) * | 2017-10-26 | 2020-08-14 | 普莱鲁德疗法有限公司 | 蛋白质精氨酸甲基转移酶5(prmt5)的选择性抑制剂 |
| CN111542525B (zh) * | 2017-10-26 | 2023-06-27 | 普莱鲁德疗法有限公司 | 蛋白质精氨酸甲基转移酶5(prmt5)的选择性抑制剂 |
| CN114127072A (zh) * | 2019-03-25 | 2022-03-01 | 加利福尼亚技术学院 | Prmt5抑制剂及其用途 |
| CN114127072B (zh) * | 2019-03-25 | 2024-10-11 | 加利福尼亚技术学院 | Prmt5抑制剂及其用途 |
| CN112679505A (zh) * | 2020-12-25 | 2021-04-20 | 杭州澳赛诺生物科技有限公司 | 一种4-甲基-7H-吡咯并[2,3-d]嘧啶的合成方法 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI622595B (zh) | 充當抗癌劑的經取代核苷衍生物 | |
| CN109890797B (zh) | 可用作抗癌剂的取代的碳核苷衍生物 | |
| CN106999479B (zh) | 可用作sumo活化酶抑制剂的杂芳基化合物 | |
| KR20150103285A (ko) | 피리미돈 유도체 및 바이러스 질환의 치료, 개선 또는 예방에서의 이의 용도 | |
| HK1241886A1 (en) | Substituted nucleoside derivatives useful as anticancer agents | |
| WO2023116748A1 (zh) | 取代的杂芳基化合物及其组合物和用途 | |
| OA18433A (en) | Substituted nucleoside derivatives useful as anticancer agents | |
| WO2016204135A1 (ja) | ５員ヘテロ環誘導体 | |
| HK40008995A (en) | Substituted carbonucleoside derivatives useful as anticancer agents | |
| HK40008995B (en) | Substituted carbonucleoside derivatives useful as anticancer agents | |
| OA20884A (en) | Cystic fibrosis transmembrane conductance regulator modulating agents. | |
| NZ748652B2 (en) | Substituted carbonucleoside derivatives useful as anticancer agents | |
| HK40012363A (en) | Inhibitors of cyclin-dependent kinase 7 (cdk7) | |
| TW201702248A (zh) | ６員雜環衍生物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1241886 Country of ref document: HK |
|
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20171020 |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1241886 Country of ref document: HK |